AbbVie vs Amgen
AbbVie reported revenue of $61.2 billion in fiscal 2025, 1.7 times Amgen's $36.8 billion in fiscal 2025. AbbVie's revenue grew 8.6% in its latest year, and Amgen's grew 9.9%. AbbVie had an operating margin of 24.6%, against 24.7% at Amgen. Free cash flow was $17.8 billion at AbbVie and $8.1 billion at Amgen.
Side by side
| AbbVie | Amgen | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $61.2B | $36.8B |
| Revenue growth | 8.6% | 9.9% |
| Revenue growth a year, last 5 years | 6.0% | 7.6% |
| Gross margin | 70.2% | 67.2% |
| Operating margin | 24.6% | 24.7% |
| Net margin | 6.9% | 21.0% |
| Free cash flow | $17.8B | $8.1B |
| Free cash flow margin | 29.1% | 22.0% |
| Return on capital | 15.7% | 14.4% |
| Net debt to EBITDA | 2.7x | 3.2x |
| Dividends and buybacks | $12.6B | $5.1B |
| Change in diluted share count | 0.0% | 0.2% |
| Last close | $286.74 | $444.63 |
| P/E at the last close | 81.0× | 27.6× |
| Insider trades, last 12 months | sold $18.9 million | sold $29.3 million |
| Piotroski F-score | 7 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AbbVieAmgen
Operating margin
Percent of revenue
AbbVieAmgen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbbVieAmgen